Background {#Sec1}
==========

Class I of major histocompatibility complex (MHC) molecules are membrane-surface proteins, which are mainly responsible for binding and presenting endogenous antigenic peptides degraded from proteins coded by virus genome in target cells \[[@CR1]\] or autoantigen \[[@CR2]\]. These endogenous antigenic peptides usually constituted by 8--10 residues in length are derived from endogenous antigens degraded by cellular proteasome \[[@CR3], [@CR4]\]. When a peptide is complexed and correctly refolded with MHC class I molecule in the antigen presenting cells (APCs), it will be presented to the membrane surface of the APCs to intrigue the cytotoxic T lymphocytes (CTLs). On this occasion, the peptide is defined as a CTL epitope \[[@CR5]\]. Once CTLs are activated by the CTL epitopes, CTLs will recognize the epitopes and then kill the infected cells \[[@CR6]\]. Therefore, the expressed MHC class I molecules on membrane of APCs should contain three components: a polymorphic heavy chain (α chain) of class I, a monomorphic light chain of β~2~-microglobulin (β~2~m) noncovalently linking the α3 domain of the heavy chain and an epitope bound in a groove formed by the α1 and α2 domains of the heavy chain \[[@CR7]\]. Analysis of structural characteristics of MHC class I is necessary so that the mechanism of antigen presentation associated with MHC class I molecules will be explored.

MHC class I genes in pigs (*Sus scrofa* domestica) located in the 7p1.1 band of the short arm of chromosome 7 are also named as swine leukocyte antigen class I (SLA-I) \[[@CR8]\]. There are three constitutively expressed classical and polymorphic SLA-I genes in the genome, namely SLA-1, SLA-2 and SLA-3 \[[@CR9]\]. Among them, SLA-2 is different from SLA-1 and SLA-3 in the N-terminal of their coding regions as previously described \[[@CR10]\]. The swine β~2~m (sβ~2~m) is monomorphic and noncovalently links with the heavy chain of the SLA-I molecules, which bind a viral or an auto CTL epitope. Foot-and-mouth disease virus (FMDV) is a great danger to cloven-hoofed animals including pigs, because it can cause animals to develop an acute, febrile, and highly contagious infectious disease \[[@CR11]\]. In FMDV, there are seven serotypes named as A, O, C, Asia1, SAT1, SAT2, and SAT3. However, none of them have mutual cross-immunity \[[@CR12], [@CR13]\]. Among them, the Asia1 serotype often occurs in Asian countries as previously reported \[[@CR14], [@CR15]\]. Therefore, to further epitope vaccine development, more CTL epitopes and their interactions with SLA-I should be investigated. Recently, crystal data of the SLA-1, SLA-2 and SLA-3 had been announced, and a few CTL epitopes derived from swine-origin influenza virus, O serotype of FMDV, Ebola virus and respiratory syndrome virus (PRRSV) were also discovered \[[@CR16]--[@CR19]\]. However, crystal of SLA-2 associated with CTL epitope derived from Asia1 serotype of FMDV remains elusive.

In this article, we introduce the expression, refolding, purification, crystallization and preliminary X-ray diffraction analysis of SLA-2\*HB01 with an AS64 CTL epitope derived from the Aisa1 serotype of FMDV.

Methods {#Sec2}
=======

Expression and isolation of the proteins of SLA-2\*HB01 and sβ~2~m {#Sec3}
------------------------------------------------------------------

To construct the expression system of the SLA-2 haplotype HB01 allele (GenBank accession No. AB602431) coding for 275 amino acids in extracellular domain, a pair of primers was designed as shown in Table [1](#Tab1){ref-type="table"}. The PCR product was recovered and cloned into pMD®19-T simple vector as previously described \[[@CR10], [@CR19]\]. After identification by digestion with *Nde* I and *Xho* I and followed by sequencing, the interest of SLA-2\*HB01 was further cloned into the pET21a (+) vector. The recombinant pET21a (+) containing the sβ~2~m had been done in our laboratory previously \[[@CR19]\]. The two recombinant SLA-2\*HB01 and sβ~2~m plasmids were induced to express in BL21 (Rosetta) *Escherichia coli* strain. The inclusion bodies were extracted as follows \[[@CR17], [@CR19]\]: In 2 L Luria--Bertani medium (LB), the SLA-2\*HB01 and sβ~2~m expression strains were inoculated and incubated at 180 rpm for 3--4 h in a shaking incubator at 37 °C until the OD~600~ value reached 0.5--0.6. Then, a final concentration of 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) was used in the medium to induce the interest of proteins to express in same cultivating environment as above. After 5 h, the bacteria were collected and cooled at 4 °C for 30 min. Then the bacteria were centrifugated for 15 min at 6000 rpm at 4 °C to collect pellets followed by washing them for three times with a solution buffer consisting of 50 mM Tris--HCl, 100 mM NaCl, 10 mM EDTA, 0.5% (*v*/v) Triton X-100, 1 mM DTT. In the end, a guanidinium chloride buffer \[6 M guanidinium chloride, 100 mM NaCl, 10 mM EDTA, 50 mM Tris--HCl pH 8.0, 10% (v/v) glycerine, 10 mM DTT\] was used to dissolve the isolated inclusion body proteins to a final concentration of 30 mg/mL.Table 1SLA-2\*HB01-AS64-sβ~2~m complex informationSource organism*Sus scrofa*DNA sourcePlasmid DNAUpper primerGGAATTC[CATATG]{.ul}GGCCCGCATTCCCTGAGCTATTCTTACLower primerAGT[CTCGAG]{.ul}TTAGTCCCATCTCAGGGTGAGGGGCTCCTGCCloning vectorpMD®19-T simpleExpression vectorpET21a (+)Expression host*E. coli* (Rosetta)Complete amino-acid sequence of the construct producedGPHSLSYSYTAVSRPDRGDSRFFIVGYVDDTQFVRFDSDAPNAKMEPRAQWIQQEGQEYWDRETQISKETAQNYRVDLNTLRGYYNQSEAGSRTIQRVYGCYLGPDGLLLRGYRQDAYDGADYIALNEDLRSWTAADMAAQITKRKWEVVNEAEGERSYLQGRCVEWLQKYLVMGKDTLQRAEPPKTHVTRHPSSDLGVTLRCWALGFYPKEISLSWQREGQDQSQDMELVETRPSGDGTFQKWAALVVPPGEEQSYTCHVQHEGLQEPLTL\
RW**ALLRSATYY***VARPPKVQVYSRHPAENGKPNYLNCYVSGFHPPQIEIDLLKNGEKMNAEQSDLSFSKDWSFYLLVHTEFTPNAVDQYSCRVKHVTLDKPKIVKWDRDH*The restriction-enzyme cleavage sites are underlined in the upper and lower primers. The normal font, bold and italics of residues expressed by the vector are from the heavy chain of SLA-2\*HB01, AS64 and the light chain of sβ~2~m in the amino-acid sequences, respectively

Refolding and purification of the SLA-2\*HB01-AS64-sβ~2~m complex {#Sec4}
-----------------------------------------------------------------

The refolded SLA-I (SLA-2\*HB01-AS64-sβ~2~m) complex was carried out as described previously \[[@CR6]\] with improvement recommended by Feng et al. \[[@CR19]\]. Firstly, the epitope AS64 (ALLRSATYY) derived from the VP1 protein residues 64--72 of Asia1 FMDV was firstly dissolved in dimethyl sulfoxide (DMSO) and then diluted in water. The inclusion body proteins of SLA-2\*HB01 and sβ~2~m were renatured and refolded with the AS64 epitope according to a 1:1:3 molar ratio by using the gradual dilution method in a refolding buffer (100 mM Tris pH 8.0, 400 mM L-Arg HCl, 2 mM EDTA, 5 mM GSH, 0.5 mM GSSH, 0.5 mM PMSF) at 4 °C. After refolding for 24 h, the soluble SLA-2\*HB01-AS64-sβ~2~m complex was further concentrated and purified by chromatography separation on a Superdex 200 16/60 HiLoad size-exclusion column (GE Healthcare) followed by an anion-exchange chromatography Resource Q (GE Healthcare). SLA-2\*HB01-AS64-sβ~2~m complex information is shown in Table [1](#Tab1){ref-type="table"}.

Crystallizing the SLA-2\*HB01-AS64-sβ~2~m complex {#Sec5}
-------------------------------------------------

The final purified SLA-2\*HB01-AS64-sβ~2~m complex proteins (\~ 44 kDa) were further dialyzed against a crystallizing buffer (50 mM NaCl, 20 mM Tris--HCl pH 8.0) overnight at 4 °C and then concentrated to 15 mg/mL. Crystallizing assays were tried with Index and Crystal Screen kit (Hampton Research) at 4 °C and 18 °C by using the sitting-drop vapor diffusion method as previously described \[[@CR19], [@CR20]\]. Two protein solution drops each with 1 μl (at 7.5 and 15 mg/mL) and 1 μL of reservoir crystallizing buffer were placed and mixed together over a well containing 120 μL reservoir solution using an MRC Maxi plate (HR3--179, Hampton Research). Crystals of SLA-2\*HB01-AS64-sβ~2~m were obtained at 14th day by using a protein concentration of 15 mg/mL in the Index solution No. 79 (0.2 M Ammonium acetate, 25% *w*/*v* PEG 3350, 0.1 M BIS-TRIS pH 6.5) at 4 °C. Crystallizing condition is shown in Table [2](#Tab2){ref-type="table"}.Table 2Crystallizing conditionMethodSitting-drop vapor diffusionTemperature (°C)4Protein concentration (mg/mL)15Buffer composition of protein solution50 mM NaCl, 20 mM Tris--HCl pH 8.0Composition of reservoir solution0.1 M BIS-TRIS pH 6.5, 0.2 M Ammonium acetate, 25% (*w*/*v*) PEG 3350Volume and ratio of drop1 μL protein solution mixed with 1 μL reservoir solutionVolume of reservoir (μL)120

Data collection and processing {#Sec6}
------------------------------

The SLA-2\*HB01-AS64-sβ~2~m crystal was firstly soaked in reservoir solution supplemented with 17% (*v*/v) glycerol as a cryoprotectant for several seconds and then flash-cooled in a nitrogen stream at − 173 °C \[[@CR21]\]. Data collection was carried out using an ADSC Q315 CCD detector at a wavelength of 1.00000 Å. By using beam line BL17U of the Shanghai Synchrotron Radiation Facility (Shanghai, China), the crystal was collected to 2.4 Å resolution. The raw data was indexed, integrated, corrected for absorption, scaled and merged using HKL-2000 \[[@CR22]\].

Results {#Sec7}
=======

After purification to homogeneity by Superdex 200 16/60 HiLoad size-exclusion chromatography, it was shown that the heavy chain of SLA-2\*HB01 was successfully refolded together with the light chain of sβ~2~m and the CTL epitope of AS64. The yield of the SLA-2\*HB01-AS64-sβ~2~m complex is about 10%. It was shown four peaks in the chromatographic elution profile (Fig. [1](#Fig1){ref-type="fig"}a). The peak 1 should be aggregated heavy chains of SLA-2\*HB01. The peaks 2--6 detected in lanes 2 to 6 with SDS-PAGE should be the refolded SLA-2\*HB01-AS64-sβ~2~m complex (44 kDa). The peak 7 detected in lane 7 with SDS-PAGE should be surplus sβ~2~m (see inset in Fig. [1](#Fig1){ref-type="fig"}a). Another peak between peak 2--6 and peak 7, not shown in SDS-PAGE detection, should be some degraded proteins according to our previous practice. The refolded SLA-2\*HB01-AS64-sβ~2~m complex was further purified by an anion-exchange chromatography Resource Q with a NaCl elution concentration of 21.5--26.5%. It was shown two peaks for the further purified complex (Fig. [1](#Fig1){ref-type="fig"}b). The peak 1 detected in lane 1 with SDS-PAGE contains free sβ~2~m. The peaks 2--4 detected in lanes 2 to 4 with SDS-PAGE contain two bands at the expected molecular weights of SLA-2\*HB01 heavy chain (32 kDa) and sβ~2~m light chain (12 kDa) (see inset in Fig. [1](#Fig1){ref-type="fig"}b).Fig. 1Purification of the refolded SLA-2\*HB01-AS64-sβ~2~m by FPLC Superdex 200 16/60 Hi-Load gel-filtration and anion-exchange chromatography Resource Q (GE Healthcare). **a** Gel-filtration profile of the refolded SLA-2\*HB01-AS64-sβ~2~m products. Peak 1 represents aggregated heavy chains of SLA-2\*HB01, peaks 2--6 represent correctly refolded SLA-2\*HB01-AS64-sβ~2~m complex (\~ 44 kDa) and peak 7 represents surplus sβ~2~m. Inset: SDS--PAGE gel detection (15%) for peaks 1, 2--6 and 7. M, the low molecular-weight protein ladder (kDa) with 97.1, 66.3, 43.0, 31.0, 20.1 and 14.4. **b** Further purification of the refolded SLA-2\*HB01-AS64-sβ~2~m by anion-exchange chromatography Resource Q. Peak 1 contains aggregated light chain of sβ~2~m, peaks 2--4 represent the refolded SLA-2\*HB01-AS64-sβ~2~m products, which was eluted with a NaCl concentration of 21.5--26.5%. Inset: SDS-PAGE gel detection (15%) for peaks 1 and 2--4. M, the low molecular-weight protein ladder (kDa) with 97.1, 66.3, 43.0, 31.0, 20.1 and 14.4

The purified SLA-2\*HB01-AS64-sβ~2~m was concentrated to 15 mg/mL for crystal screening. Crystals occurred after 7 days in the Index solution No. 79 at 4 °C and then they were harvested at 14th d (Fig. [2](#Fig2){ref-type="fig"}). After preliminary X-ray diffraction analysis, it was shown that the diffraction resolution of the SLA-2\*HB01-AS64-sβ~2~m crystal used for data collection was 2.4 Å. The space group of the crystal belongs to P2~1~2~1~2~1~. The unit-cell parameters of the crystal were shown as a = 48.37, b = 97.75, c = 166.163 Å (Fig. [3](#Fig3){ref-type="fig"}). The crystal has a solvent content of 61.9%. Data-collection and processing statistics are summarized in Table [3](#Tab3){ref-type="table"}.Fig. 2Picture of the SLA-2\*HB01-AS64-sβ2m crystal growing in the Index solution No. 79 at 4 °CFig. 3Diffraction pattern of the SLA-2\*HB01-AS64-sβ~2~m complex. Spots corresponding to diffraction to high resolution are highlighted in the boxTable 3X-ray diffraction data and processing statistics. Values in parentheses are for the highest resolution shellDiffraction sourceBL17U, SSRFWavelength (Å)1.00000Temperature (°C)−173DetectorADSC Q315 CCDCrystal-to-detector distance (mm)350.00Space groupP2~1~2~1~2~1~Unit-cell parameters (Å)a = 48.37, b = 97.75, c = 166.16Resolution range (Å)50.0--2.40 (2.40--2.49) ^a^Total No. of reflections222,792No. of unique reflections31,827Completeness (%)99.2Average *I/σ*(*I*)21.8R~merge~^b^ (%)7.8 (31.8)Redundancy7.0 (7.1)^a^Values in parentheses refer to statistics in the outermost resolution shell^b^R~merge~ = ∑~hkl~∑~i~ ∣I~i~ -〈I〉∣∑~hkl~∑~i~I~i~, where I~i~ is the observed intensity and 〈I〉 is the average intensity of multiple observations of symmetry related reflections

Discussion {#Sec8}
==========

Previously, we reported a multiple amino-acid sequence alignment between SLA-2\*HB01 and other known MHC class I alleles in swine, human and mouse \[[@CR10]\]. Based on human HLA-A2 crystal data, the structure of SLA-2\*HB01 was predicted by using homology modeling. We noticed SLA-2\*HB01 preserved some key functional sites of HLA-A2 and H-2, which indicated that SLA-2\*HB01 should be crucial in binding and presenting antigenic peptides \[[@CR23], [@CR24]\]. In addition, SLA-2\*HB01 has 85.0--93.9, 86.2--97.0 and 83.3--88.6% sequence identity to other SLA-1, SLA-2 and SLA-3 alleles, respectively. Comprehensive analysis of SLA-2\*HB01, it should be a novel allele of SLA-2 with specific genetic characteristics \[[@CR10]\].

In this work, the crystal of the SLA-2\*HB01 molecule complexed with swine β~2~m and a CTL epitope AS64 derived from the Asia1 serotype of FMDV was reported. It seems the space group type of SLA-2\*HB01-AS64-sβ~2~m crystal is consistent with that of SLA-1 crystal but quite different from that of SLA-3 crystal, which indicates the structure of SLA-2 might be more similar to that of SLA-1 \[[@CR17], [@CR18]\]. Recently, a crystal of SLA-2\*HB01 complex associated with an Hu64 CTL epitope derived from O serotype of FMDV was reported. It was shown that the two crystals were similar in space group type, but different in unit-cell parameters \[[@CR19]\]. To learn about the elaborate structural characteristics of SLA-2, especially the special characteristics that differ from SLA-1 and SLA-3, the 3-dimentional structure of the SLA-2 complex associated more CTL epitopes derived from swine-origin virus is required to be revealed as soon as possible.

Conclusions {#Sec9}
===========

The research data will be used to further elucidate the 3-dimentional structure of the SLA-2 molecules and design more refined viral epitopes.
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